Literature DB >> 10605047

Expansion of tumor-T cell pairs from fine needle aspirates of melanoma metastases.

M C Panelli1, A Riker, U Kammula, E Wang, K H Lee, S A Rosenberg, F M Marincola.   

Abstract

Lymphocytes expanded from excised specimens can be used to characterize intratumoral T cell responses. These analyses, however, are limited to one time point in the natural history of the removed tumor. The expansion of autologous tumor cells and tumor-infiltrating lymphocytes (TIL) from fine needle aspirates (FNA) of tumors potentially allows a dynamic evaluation of T cell responses within the same lesion at moments relevant to the disease course or response to therapy. Fourteen TIL cultures and 8 tumor cell lines were generated from 18 FNA (12 patients). Five of six TIL that could be tested against autologous tumor demonstrated specific reactivity. Two additional TIL for which no autologous tumor was available demonstrated recognition of HLA-matched melanoma cell lines. Serial FNA of the same lesions were performed in five HLA-A*0201 patients vaccinated with the emulsified melanoma Ag (MA) epitopes: MART-1:27-35; tyrosinase:368-376(370D); gp100:280-288(288V); and gp100:209-217 (210M). FNA material was separately cultured for a short time in IL-2 (300 IU/ml) after stimulation with irradiated autologous PBMC pulsed with each peptide or FluM1:58-66 (1 micromol/ml). No peptide-specific TIL could be expanded from prevaccination FNA. However, after vaccination, TIL specific for gp100:280(g280), gp100:209 (g209), and MART-1:27-35 (MART-1)-related epitopes were identified in three, three, and two patients, respectively. No Flu reactivity could be elicited in TIL, whereas it was consistently present in parallel PBMC cultures. This excluded PBMC contamination of the FNA material. This analysis suggests the feasibility of TIL expansion from minimal FNA material and localization of vaccine-specific T cells at the tumor site.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10605047     DOI: 10.4049/jimmunol.164.1.495

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  How much help does a vaccine-induced T-cell response need?

Authors:  J S Weber; J J Mulé
Journal:  J Clin Invest       Date:  2001-03       Impact factor: 14.808

2.  Functional heterogeneity of vaccine-induced CD8(+) T cells.

Authors:  Vladia Monsurrò; Dirk Nagorsen; Ena Wang; Maurizio Provenzano; Mark E Dudley; Steven A Rosenberg; Francesco M Marincola
Journal:  J Immunol       Date:  2002-06-01       Impact factor: 5.422

3.  Intensity of the vaccine-elicited immune response determines tumor clearance.

Authors:  Ainhoa Perez-Diez; Paul J Spiess; Nicholas P Restifo; Polly Matzinger; Francesco M Marincola
Journal:  J Immunol       Date:  2002-01-01       Impact factor: 5.422

4.  Comparison of three culture media for the establishment of melanoma cell lines.

Authors:  M C Pandolfino; S Saïagh; A C Knol; B Dréno
Journal:  Cytotechnology       Date:  2010-08-21       Impact factor: 2.058

Review 5.  Understanding the response to immunotherapy in humans.

Authors:  Ena Wang; Monica C Panelli; Francesco M Marincola
Journal:  Springer Semin Immunopathol       Date:  2005-01-22

Review 6.  Functional roles of immature dendritic cells in impaired immunity of solid tumour and their targeted strategies for provoking tumour immunity.

Authors:  R Kim; M Emi; K Tanabe
Journal:  Clin Exp Immunol       Date:  2006-11       Impact factor: 4.330

7.  Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors.

Authors:  Andrea Worschech; Maciej Kmieciak; Keith L Knutson; Harry D Bear; Aladar A Szalay; Ena Wang; Francesco M Marincola; Masoud H Manjili
Journal:  Cancer Res       Date:  2008-04-01       Impact factor: 12.701

Review 8.  Overview of melanoma vaccines and promising approaches.

Authors:  Monica C Panelli; Ena Wang; Vladia Monsurrò; Ping Jin; Katia Zavaglia; Kina Smith; Yvonne Ngalame; Francesco M Marincola
Journal:  Curr Oncol Rep       Date:  2004-09       Impact factor: 5.075

Review 9.  Active antigen-specific immunotherapy of melanoma: from basic science to clinical investigation.

Authors:  Giulio C Spagnoli; Michel Adamina; Martin Bolli; Walter P Weber; Paul Zajac; Walter Marti; Daniel Oertli; Michael Heberer; Felix Harder
Journal:  World J Surg       Date:  2005-06       Impact factor: 3.282

Review 10.  Identification of human tumor antigens recognized by T-cells and their use for immunotherapy.

Authors:  Yutaka Kawakami
Journal:  Int J Hematol       Date:  2003-06       Impact factor: 2.319

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.